Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 3, 2006, Pages 264-274

  Renda, Giulia ^a   Tacconelli, Stefania ^a   Capone, Marta L ^a   Sacchetta, Daniele ^a   Santarelli, Francesco ^a   Sciulli, Maria G ^a   Zimarino, Marco ^a   Grana, Marilena ^a   D'Amelio, Elisabetta ^a   Zurro, Maria ^a   Price, Thomas S ^a   Patrono, Carlo ^a   De Caterina, Raffaele ^a   Patrignani, Paola ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTIDIABETIC AGENT; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; LOOP DIURETIC AGENT; PLACEBO; PROSTAGLANDIN E2; THROMBOXANE; THROMBOXANE B2;

ADULT; AGED; ANTICOAGULATION; ARACHIDONIC ACID METABOLISM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EPIGASTRIC PAIN; ERYTHEMA; FEMALE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; KNEE OSTEOARTHRITIS; LONG TERM CARE; MALE; MEDICAL ASSESSMENT; NAUSEA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SIDE EFFECT; SKIN MANIFESTATION; SKIN PRURITUS; STEADY STATE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOGENESIS; URINARY EXCRETION; VOMITING;

ADENOSINE DIPHOSPHATE; AGED; ARACHIDONIC ACID; ASPIRIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OSTEOARTHRITIS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PYRAZOLES; SULFONAMIDES; THROMBOXANE B2; TREATMENT OUTCOME;

EID: 33748146072     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.05.004     Document Type: Article

References (42)

1. Patrono C., Coller B., FitzGerald G.A., Hirsh J., and Roth G. Platelet active drug the relationships among dose, effectiveness, and side effects. Chest 126 (2004) 234S-264S
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
3. Roth G.J., and Majerus P.W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 56 (1975) 624-632
4. Egan K.M., Wang M., Fries S., Lucitt M.B., Zukas A.M., Pure E., et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111 (2005) 334-342
5. Patrignani P., Filabozzi P., and Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69 (1982) 1366-1372
6. Capone M.L., Tacconelli S., Sciulli M.G., Grana M., Ricciotti E., Minuz P., et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109 (2004) 1468-1471
7. Pedersen A.K., and FitzGerald G.A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 311 (1984) 1206-1211
8. Reilly I.A., and FitzGerald G.A. Inhibition of thromboxane formation in vivo and ex vivo implications for therapy with platelet inhibitory drugs. Blood 69 (1987) 180-186
9. Minuz P., Gaino S., Zuliani V., Tommasoli R.M., Benati D., Ortolani R., et al. Functional role of p38 mitogen activated protein kinase in platelet activation induced by a thromboxane A2 analogue and by 8-iso-prostaglandin F2alpha. Thromb Haemost 87 (2002) 888-898
10. 2 in patients chronically treated with aspirin. J Thromb Haemost 3 (2005) 2784-2789
11. Maree A.O., Curtin R.J., Dooley M., Conroy R.M., Crean P., Cox D., et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 46 (2005) 1258-1263
12. Garcia Rodriguez L.A., Varas C., and Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 11 (2000) 382-387
13. Ray W.A., Stein C.M., Daugherty J.R., Hall K., Arbogast P.G., and Griffin M.R. Non-steroidal anti-inflammatory drugs and risk of coronary heart disease an observational cohort study. Lancet 359 (2002) 118-123
14. Garcia Rodriguez L.A., Varas-Lorenzo C., Maguire A., and Gonzalez-Perez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109 (2004) 3000-3006
15. Howard P.A., and Delafontaine P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk. J Am Coll Cardiol 43 (2004) 519-525
16. Hippisley-Cox J., and Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330 (2005) 1366-1372
17. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tournier B., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
18. Farkouh M.E., Kirshner H., Harrington R.A., Ruland S., Verheugt F.W., Schnitzer T.J., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364 (2004) 675-684
19. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
20. MacDonald T.M., and Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361 (2003) 573-574
21. Kurth T., Glynn R.J., Walker A.M., Chan K.A., Buring J.E., Hennekens C.H., et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108 (2003) 1191-1195
22. Kimmel S.E., Berlin J.A., Reilly M., Jaskowiak J., Kishel L., Chittams J., et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 43 (2004) 985-990
23. Curtis J.P., Wang Y., Portnay E.L., Masoudi F.A., Havranek E.P., and Krumholz H.M. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ 327 (2003) 1322-1323
24. Capone M.L., Sciulli M.G., Tacconelli S., Grana M., Ricciotti E., Renda G., et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45 (2005) 1295-1301
25. Dallob A., Hawkey C.J., Greenberg H., Wight N., De Schepper P., Waldman S., et al. Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J Clin Pharmacol 43 (2003) 573-585
26. Wilner K.D., Rushing M., Walden C., Adler R., Eskra J., Noveck R., et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol 42 (2002) 1027-1030
27. Patrignani P., Sciulli M.G., Manarini S., Santini G., Cerletti C., and Evangelista V. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 50 (1999) 661-667
28. 2 production in healthy subjects. Thromb Res 17 (1980) 317-327
29. European Medicines Web site. 2005. Available from: URL:http://www.cbg-meb.nl/uk/docs/nieuws/pb-cox-2-review.pdf#search='EME A%20and%20Cox2%20inhibitors%20april%202005.
30. 2 in man. Biochim Biophys Acta 992 (1989) 66-70
31. FitzGerald G.A., Pedersen A.K., and Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67 (1983) 1174-1177
32. Pedersen A.K., and FitzGerald G.A. Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing. Clin Pharmacol Ther 37 (1985) 36-42
33. Mammen E.F., Comp P.C., Gosselin R., Greenberg C., Hoots W.K., Kessler C.M., et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 24 (1998) 195-202
34. Patrignani P., Panara M.R., Greco A., Fusco O., Natoli C., Iacobelli S., et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271 (1994) 1705-1712
35. Available from: URL:www.cran.r-project.org.
36. Carpenter J.R., Goldstein H., and Rasbash J. A novel bootstrap procedure for assessing the relationship between class size and achievement. J R Stat Soc Ser C Appl Stat 52 (2003) 431-443
37. Sciulli M.G., Renda G., Capone M.L., Tacconelli S., Ricciotti E., Manarini S., et al. Heterogeneity in the suppression of platelet cyclooxygenase 1 activity by aspirin in coronary heart disease. Clin Pharmacol Ther 80 (2006) 115-125
38. Grosser T., Fries S., and Fitzgerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116 (2006) 4-15
39. Cryer B., Berlin R.G., Cooper S.A., Hsu C., and Wason S. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther 27 (2005) 185-191
40. Hudson M., Baron M., Rahme E., and Pilote L. Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. J Rheumatol 32 (2005) 1589-1593
41. Curtis J.P., and Krumholz H. The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs: is it time to believe the hype?. J Am Coll Cardiol 43 (2004) 991-993
42. Public health advisory: non-steroidal anti-inflammatory drug products (NSAIDS). 2004. US Food and Drug Administration Web site. Available from: URL:http://www.fda.gov/cder/drug/advisory/nsaids.htm.